🔥36氪•Freshcollected in 13m
Active Tech raises 330M RMB in record BCI funding
💡Record-breaking funding in BCI signals a major shift in the intersection of neuroscience and embodied AI.
⚡ 30-Second TL;DR
What Changed
Raised 330 million RMB in angel round
Why It Matters
This significant funding signals a major capital push into the Chinese BCI market, which is a critical frontier for embodied AI and neural interface research.
What To Do Next
Track the clinical trial progress of Active Tech to understand the state of invasive BCI hardware in the Chinese market.
Who should care:Researchers & Academics
Key Points
- •Raised 330 million RMB in angel round
- •Focus on invasive brain-computer interface (BCI) technology
- •Funds allocated for clinical trials and team expansion
🧠 Deep Insight
AI-generated analysis for this event.
🔑 Enhanced Key Takeaways
- •Active Tech was founded by a team of neuroscientists and engineers from top-tier Chinese research institutions, specifically focusing on high-density neural signal acquisition.
- •The company's proprietary technology utilizes a flexible electrode array designed to minimize glial scarring, a common challenge in long-term invasive BCI stability.
- •This funding round was led by a consortium of specialized deep-tech venture capital firms, including several state-backed funds focused on the 'New Quality Productive Forces' initiative.
- •Active Tech plans to utilize a portion of the capital to establish a GMP-compliant manufacturing facility to support upcoming human clinical trials.
- •The company is developing a custom low-power ASIC (Application-Specific Integrated Circuit) to handle on-chip signal processing, reducing the data transmission burden for the implant.
📊 Competitor Analysis▸ Show
| Competitor | Technology Type | Key Advantage | Clinical Status |
|---|---|---|---|
| Neuralink | Invasive | High-bandwidth robotic insertion | Human Trials |
| Synchron | Endovascular | Minimally invasive (stent-based) | Human Trials |
| NeuraMatrix | Invasive | High-density neural recording | Pre-clinical |
| BrainCo | Non-Invasive | Consumer/Prosthetic focus | Commercialized |
🛠️ Technical Deep Dive
- Electrode Material: Utilizes biocompatible flexible polymer substrates to match the mechanical modulus of brain tissue.
- Signal Processing: Implements on-chip spike sorting and data compression to reduce power consumption and heat dissipation.
- Data Transmission: Employs ultra-low-power wireless telemetry for real-time brain-to-external device communication.
- Insertion Method: Developing a robotic surgical platform to ensure precise placement of high-density arrays while minimizing vascular damage.
🔮 Future ImplicationsAI analysis grounded in cited sources
Active Tech will initiate first-in-human clinical trials within 18 months.
The scale of the angel funding and the stated focus on clinical trials suggest a rapid transition from pre-clinical validation to regulatory approval processes.
The company will pivot toward a closed-loop BCI system.
The development of on-chip signal processing indicates an intent to move beyond simple data recording to real-time neural stimulation and feedback.
⏳ Timeline
2025-06
Active Tech officially incorporated in China.
2026-01
Successful completion of long-term biocompatibility testing in animal models.
2026-08
Secured 330 million RMB in record-breaking angel funding round.
📰
Weekly AI Recap
Read this week's curated digest of top AI events →
👉Related Updates
AI-curated news aggregator. All content rights belong to original publishers.
Original source: 36氪 ↗